New facility for Ruconest production

Pharming Group N.V. will be building a new facility to expand the company’s downstream processing capacity for its lead product, Ruconest (recombinant C1 esterase inhibitor (rhC1INH).

The downstream processing facility will include the purification, filtration and concentration of the starting material. Construction is planned to begin mid-2021 at Pivot Park in Oss, the Netherlands. Pivot Park is also the location of BioConnection B.V., Pharming’s contracted fill and finish facility, in which Pharming holds a minority stake.

At Pivot Park, Pharming will move into a new, sustainable, five-story building with a total floor space of approximately 4,000 m². The building has been specially designed for the company and is located in a prominent position on the site. It is the first new building on the campus and CEO Drees hopes many more will follow. Pharming’s arrival at Pivot Park will create at least 40 new jobs in Oss.

Sijmen de Vries, CEO of Pharming: “With an increasing demand for Ruconest® for the treatment of HAE and an increasing need for rhC1INH in our clinical trials in new, large indications, we continue to invest in expanding our in-house processing capabilities as part of our strategy to deliver long-term growth.”
(Source: Pharming)

2020-11-19T08:12:42+01:00November 19, 2020|HAEi News|